Obrixtamig

Phase 3Small molecule

Boehringer Ingelheim

Obrixtamig is one of 45 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerActive, not recruiting

Small Cell Lung Cancer ( SCLC )Recruiting

Extrapulmonary Neuroendocrine CancerNot yet recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Small Cell Lung Cancer ( SCLC )Phase 3

Recruiting

Extrapulmonary Neuroendocrine CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

34 2

Imfinzi

AstraZeneca

Phase 3

33 3

Tecentriq

Roche

Phase 3

31 4

Zepzelca

Jazz Pharmaceuticals

Phase 3

10 5

Lenvima

Eisai

Phase 3

5 6

Camptosar

EEastern Cooperative Oncology Group

Phase 3

13 7

Trodelvy

Gilead

Phase 3

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 9

Ifex

BBaxter Healthcare Corporation

Phase 3

5 10

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Small Cell Lung Cancer ( SCLC )

NCT07472517

Q1 2031

Phase 3Not yet recruiting

Extrapulmonary Neuroendocrine Cancer

NCT07544654

Clinical

Trials by Indication[1]

Small Cell Lung Cancer1 trial

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05879978·45 enrolled

Extrapulmonary Neuroendocrine Cancer1 trial

A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

Not yet recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT07544654·390 enrolled

Small Cell Lung Cancer ( SCLC )1 trial

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT07472517·670 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Obrixtamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Obrixtamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Obrixtamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Obrixtamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q1 2031

Trials by Indication[1]

Small Cell Lung Cancer1 trial

Extrapulmonary Neuroendocrine Cancer1 trial

Small Cell Lung Cancer ( SCLC )1 trial

References

Drug Info

Quick Facts

Related News